We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

309 hedge funds and large institutions have $3.42B invested in Ultragenyx Pharmaceutical in 2025 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 117 increasing their positions, 108 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more call options, than puts

Call options by funds: $149M | Put options by funds: $87.7M

26% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 43

5% more capital invested

Capital invested by funds: $3.25B → $3.42B (+$169M)

3% more funds holding

Funds holding: 299 → 309 (+10)

2.47% more ownership

Funds ownership: 97.11% → 99.58% (+2.5%)

8% more repeat investments, than reductions

Existing positions increased: 117 | Existing positions reduced: 108

14% less funds holding in top 10

Funds holding in top 10: 7 → 6 (-1)

Holders
309
Holders Change
+10
Holders Change %
+3.34%
% of All Funds
4.07%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.08%
New
54
Increased
117
Reduced
108
Closed
43
Calls
$149M
Puts
$87.7M
Net Calls
+$60.8M
Net Calls Change
+$59.2M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$106M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$80.1M
3
BBA
Baker Bros. Advisors
New York
+$43.1M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$34.2M
5
FCM
Farallon Capital Management
California
+$32.4M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$22.3M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$20.8M
3
VPC
Vestal Point Capital
New York
-$18.1M
4
ACA
Avoro Capital Advisors
New York
-$18M
5
Invesco
Invesco
Georgia
-$17.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
TC
276
Truvestments Capital
Florida
$3.96K – – –
MAM
277
Meeder Asset Management
Ohio
$3.85K +$3.82K +106 New
GWSG
278
GPS Wealth Strategies Group
Colorado
$3.64K – – –
BCM
279
Boreal Capital Management
Florida
$3.64K +$3.6K +100 New
Jones Financial Companies
280
Jones Financial Companies
Missouri
$3.18K -$288 -8 -8%
S
281
Sachetta
Massachusetts
$3.13K +$3.1K +86 New
Nisa Investment Advisors
282
Nisa Investment Advisors
Missouri
$2.91K – – –
WTA
283
Washington Trust Advisors
Massachusetts
$2.89K +$2.56K +71 +888%
PTC
284
Private Trust Company
Ohio
$2.62K – – –
AssetMark Inc
285
AssetMark Inc
California
$2.18K +$1.95K +54 +900%
AAP
286
Arax Advisory Partners
Colorado
$2K -$829 -23 -29%
WA
287
WPG Advisers
Maryland
$1.89K – – –
GRP
288
Global Retirement Partners
California
$1.64K +$1.62K +45 New
CIAM
289
Caitong International Asset Management
Hong Kong
$1.16K +$1.01K +28 +700%
BFS
290
Bare Financial Services
Pennsylvania
$1.13K +$1.12K +31 New
WSFS
291
Wilmington Savings Fund Society
Delaware
$1.02K – – –
GWM
292
Geneos Wealth Management
Colorado
$982 -$4.72K -131 -83%
CTC
293
Central Trust Company
Missouri
$873 – – –
FFA
294
Farther Finance Advisors
California
$691 – – –
CT
295
Clearstead Trust
Maine
$691 +$685 +19 New
MCM
296
MV Capital Management
Maryland
$582 +$433 +12 +300%
SS
297
SBI Securities
Japan
$545 – – –
CFO
298
CVA Family Office
Colorado
$509 +$505 +14 New
PWMG
299
Private Wealth Management Group
New Jersey
$437 -$793 -22 -65%
BIA
300
Bell Investment Advisors
California
$400 – – –
10 11
12
13 14

RARE Hedge Fund Activity: Q2 2025 in Review

309 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2025, worth a combined $3.42B — up 5.2% from $3.25B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new RARE positions and 43 closed out — a net gain of 11 holders — while 117 added to existing stakes and 108 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $106M. The largest seller was Adage Capital Partners, cutting an estimated $22.3M.

  • 309 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2025, up from 299 in Q1 2025.
  • Funds reported $3.42B of Ultragenyx Pharmaceutical stock for Q2 2025, up 5.2% quarter-over-quarter.
  • 54 funds opened new Ultragenyx Pharmaceutical positions in Q2 2025 and 43 closed out, a net change of +11 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q2 2025 was JP Morgan Chase, an estimated $106M added.
  • The largest Ultragenyx Pharmaceutical seller in Q2 2025 was Adage Capital Partners, an estimated $22.3M sold.

Based on aggregated 13F filings for Q2 2025.